Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Writing PET into existence.

Literature DB >> 24072349

Writing PET into existence.

A Chiti¹, M Kirienko, E Incerti, M Picchio.

Abstract

Mesh：

Substances：

Year: 2013 PMID： 24072349 DOI： 10.1007/s00259-013-2573-x

Source DB: PubMed Journal: Eur J Nucl Med Mol Imaging ISSN： 1619-7070 Impact factor: 9.236

Keyword Cloud
References

× No keyword cloud information.

41 in total

1. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.

Authors: Ying Chen; Mrudula Pullambhatla; Catherine A Foss; Youngjoo Byun; Sridhar Nimmagadda; Srinivasan Senthamizhchelvan; George Sgouros; Ronnie C Mease; Martin G Pomper
Journal: Clin Cancer Res Date: 2011-10-31 Impact factor: 12.531

2. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy.

Authors: Giampiero Giovacchini; Maria Picchio; Vincenzo Scattoni; Rita Garcia Parra; Alberto Briganti; Luigi Gianolli; Francesco Montorsi; Cristina Messa
Journal: Eur J Nucl Med Mol Imaging Date: 2010-03-20 Impact factor: 9.236

3. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis.

Authors: Sebastian Mannweiler; Peter Amersdorfer; Slave Trajanoski; Jonathan A Terrett; David King; Gabor Mehes
Journal: Pathol Oncol Res Date: 2008-09-18 Impact factor: 3.201

Review 4. Molecular imaging of prostate cancer: PET radiotracers.

Authors: Hossein Jadvar
Journal: AJR Am J Roentgenol Date: 2012-08 Impact factor: 3.959

5. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

Authors: Axel Heidenreich; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Nicolas Mottet; Hans-Peter Schmid; Theo van der Kwast; Thomas Wiegel; Filliberto Zattoni
Journal: Eur Urol Date: 2010-10-28 Impact factor: 20.096

Writing PET into existence.

1. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.

2. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy.

3. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis.

Review 4. Molecular imaging of prostate cancer: PET radiotracers.

5. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

Review 6. Clinical evidence on PET/CT for radiation therapy planning in prostate cancer.

Review 7. Prostate-specific membrane antigen-based imaging.

Review 8. Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations.

Review 9. Role of choline PET/CT in guiding target volume delineation for irradiation of prostate cancer.

10. PSMA as a target for radiolabelled small molecules.